azacitidine has been researched along with Sclerosis, Systemic in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beyer, C; Dees, C; Distler, A; Distler, JH; Distler, O; Funke, R; Lin, NY; Palumbo-Zerr, K; Schett, G; Schlottmann, I; Zerr, P | 1 |
| Huang, JH; Kanekura, T; Li, YP; Liu, RZ; Lu, QJ; Shu, Y; Sun, XH; Wang, JC; Wang, Q; Wang, YY; Xiao, R; Zhao, M | 1 |
| Lu, Q; Luo, Y; Shu, Y; Wang, Y; Xiao, R | 1 |
| Baron, F; Beguin, Y; Caers, J; Conteduca, G; Delens, L; Delvenne, P; Drion, P; Dubois, S; Ehx, G; Fransolet, G; Hannon, M; Humblet-Baron, S; Muller, J; Somja, J | 1 |
| Fan, PS; Kahaleh, B; Wang, Y | 1 |
1 review(s) available for azacitidine and Sclerosis, Systemic
| Article | Year |
|---|---|
Epigenetic mechanisms: An emerging role in pathogenesis and its therapeutic potential in systemic sclerosis.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Biomarkers; CD27 Ligand; CD40 Antigens; Decitabine; DNA Methylation; Epigenesis, Genetic; Extracellular Matrix; Fibrosis; Histone Deacetylase Inhibitors; Histones; Humans; MicroRNAs; Protein Processing, Post-Translational; Proto-Oncogene Protein c-fli-1; Scleroderma, Systemic; Signal Transduction | 2015 |
4 other study(ies) available for azacitidine and Sclerosis, Systemic
| Article | Year |
|---|---|
The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis.
Topics: Adult; Aged; Animals; Azacitidine; Case-Control Studies; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Down-Regulation; Enzyme Inhibitors; Epigenesis, Genetic; Female; Fibroblasts; Humans; Intercellular Signaling Peptides and Proteins; Leukocytes, Mononuclear; Male; Membrane Proteins; Mice; Middle Aged; Promoter Regions, Genetic; Scleroderma, Systemic; Wnt Signaling Pathway; Young Adult | 2014 |
DNA hypermethylation of the forkhead box protein 3 (FOXP3) promoter in CD4+ T cells of patients with systemic sclerosis.
Topics: Adult; Antimetabolites; Azacitidine; CD4-Positive T-Lymphocytes; DNA Methylation; Down-Regulation; Female; Forkhead Transcription Factors; Humans; Male; Scleroderma, Systemic; T-Lymphocytes, Regulatory | 2014 |
Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Transplantation; Cell Proliferation; DNA Methylation; Drug Administration Schedule; Forkhead Transcription Factors; Graft vs Host Disease; Lymphocyte Count; Mice; Mice, Inbred BALB C; Scleroderma, Systemic; Spleen; T-Lymphocytes, Regulatory | 2016 |
Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts.
Topics: Azacitidine; Cells, Cultured; Collagen Type I; CpG Islands; DNA Methylation; DNA Modification Methylases; Epigenesis, Genetic; Fibroblasts; Gene Expression Regulation; Genes, Suppressor; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Phenotype; Promoter Regions, Genetic; Proto-Oncogene Protein c-fli-1; Scleroderma, Systemic; Signal Transduction; Skin; Transfection | 2006 |